Terms ending in 2037
Every in-force patent on Epicentrx, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,342,778 | Treatment of Brain Metastases Using Organonitro Compound Combination Therapy In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 12,357,607 | Compositions and Methods for Intravenous Administration of 2-Bromo-1-(3,3-Dinitroazetidin-1-YL)ETHANONE In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 10,906,957 | Immunomodulatory Fusion Proteins In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 12,054,530 | Immunomodulatory Fusion Proteins In force · Low confidence | Epicentrx, Inc. | In force | Low confidence | |
| US 11,008,287 | Sulfoxyalkyl Organonitro and Related Compounds and Pharmaceutical Compounds for Use in Medicine In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 10,232,053 | Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of Cancer In force · High confidence | Epicentrx, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.